Increases sexual desire and function for men and women:
- Minimal or no undesirable side effects.
- Decrease body fat mass and reduce food intake.
- Induces skin tanning at low doses.
- Potent self-tanner applications.
Melanotan II also known as PT-141 was developed by researchers
at the University of Arizona College of Medicine. Melanotan II
is an analog of the peptide hormone alpha-melanocyte stimulating
hormone (?-MSH), this hormone provides a therapeutic tan with
the ability to lower the risk of skin cancer, (MSH) also plays
an important role in regulating sexual arousal in men and women.
Melanotan II has the additional effect of decreasing body fat
mass. Melanotan II It is a cyclic lactyam analog of alpha-MSH
with the amino acid sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2.
Melanotan II is in a class of
peptide hormone known as Melanocortins (MCs). Melanocortins (MCs)
are multifunctional peptide hormones that regulate a diversity
of physiological functions. MCs have been implicated in sexual
function in animals.
A MC analog, Melanotan II (MTII), can enhance sexual function
in human males (erectile activity) and females (increased levels
of sexual desire and genital arousal). Unlike other sexual-enhancement
drugs, MTII works at the level of the brain, thus eliciting a
rather natural sexual response with minimal or no undesirable
side effects. The actions of the peptide were discovered accidentally
while studying the effects of the peptide and related analogs
on human skin pigmentation (tanning). Hadley ME (2005).
Melanotan II, PT-141,
a cyclic heptapeptide melanocortin analog, was evaluated following
subcutaneous administration to healthy male subjects and to patients
with erectile dysfunction (ED) who report an inadequate response
to Viagra. The erectile response induced by PT-141 was statistically
significant at both doses. PT-141 was safe and well tolerated
in both studies. The erectogenic potential of PT-141, its tolerability
profile and its ability to cause significant erections in patients
who do not have an adequate response to a PDE5 inhibitor suggest
that PT-141 may provide an alternative treatment for ED with a
potentially broad patient base.Rosen RC, Diamond LE, Earle DC,
Shadiack AM,Molinoff PB (2004).
In addition to the sexual enhancement and tanning effects of
Melanotan II, MT-II has also exhibited the potential to decrease
body fat mass and reduce food intake. Choi YH, Li C, Hartzell
DL, Lin J, Della-Fera MA, Baile CA (2003).
MT-II has tanning activity in humans given only 5 low doses every
other day by subcutaneous injection. The recommended single MT-II
dose for future Phase I studies is 0.025 mg/kg/day.
